Liqrev (sildenafil oral suspension) / CMP Pharma - LARVOL DELTA

A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH) (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: University of Utah | Trial completion date: Sep 2025 ➔ Sep 2026 | Trial primary completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Cardiovascular • Gastroenterology • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Bedtime sildenafil oral suspension improves sexual spontaneity and time-concerns compared to on-demand treatment in men with erectile dysfunction: results from a real-life, cross-sectional study. (PubMed, Int J Impot Res) - "On-demand sildenafil has proved to be an effective PDE5i but with lower spontaneity scores compared to daily tadalafil treatment. Bedtime sildenafil OSF showed similar efficacy but better spontaneity scores than on-demand use. Bedtime sildenafil is a valuable option for men with ED prioritizing efficacy and sexual spontaneity."

Journal • Observational data • Erectile Dysfunction

Effectiveness and patient satisfaction with the new sildenafil oral suspension formulation compared to sildenafil oro-dispersible film: a real-life study. (PubMed, Int J Impot Res) - "At multivariable logistic regression analysis, younger age (p = 0.02) and lower baseline IIEF-EF scores (p = 0.01) were independent predictors of improved satisfaction with OSF compared to ODF. The sildenafil OSF and ODF had similar efficacy, however the new OSF provides higher satisfaction and spontaneity scores compared to the oro-dispersible film."

Journal • Erectile Dysfunction

Sildenafil oral suspension formulation for erectile dysfunction: is it love at first sight? (PubMed, Int J Impot Res) - No abstract available

Journal • Erectile Dysfunction

A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH) (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: University of Utah | Trial completion date: Sep 2023 ➔ Sep 2025 | Trial primary completion date: Mar 2023 ➔ Mar 2025

Trial completion date • Trial primary completion date • Cardiovascular • Gastroenterology • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Sotatercept (Winrevair) for pulmonary arterial hypertension. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

CMP Pharma, Inc Announces that Liqrev, the First and Only Ready-made FDA-approved Liquid Suspension of Sildenafil is Now Available (PRNewswire) - "CMP Pharma, Inc. announced today that Liqrev (Sildenafil) Oral Suspension, 10 mg/mL, the first and only FDA-approved ready-made oral liquid of sildenafil, is now available....FDA-approved Liqrev addresses the inconsistencies that come from unapproved crushed or compounded tablets and removes the need for complex preparation of powder formulations. Liqrev has a strawberry flavor and is available in 122 mL bottles with a 24-month shelf life."

Launch US • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases